AbbVie Inc. $ABBV Shares Sold by Torray Investment Partners LLC

Key Points

• Torray Investment Partners cut its stake in AbbVie by 8.8% in Q4, selling 8,945 shares and leaving 92,687 shares valued at about $21.18 million (≈3.0% of Torray’s portfolio and its 10th largest holding).
• The U.S. FDA declined to approve AbbVie’s trenibotulinumtoxinE and issued a Complete Response Letter citing manufacturing/CMC issues, delaying potential cosmetic-market revenue and adding remediation risk.
• AbbVie announced a planned $1.4 billion, 185‑acre advanced manufacturing campus in Durham, NC — its largest single-site capital commitment aimed at increasing capacity for immunology, neuroscience and oncology medicines.

Torray Investment Partners LLC cut its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 8.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,687 shares of the company's stock after selling 8,945 shares during the period. AbbVie accounts for approximately 3.0% of Torray Investment Partners LLC's investment portfolio, making the stock its 10th biggest holding. Torray Investment Partners LLC's holdings in AbbVie were worth $21,178,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Financial Symmetry Inc bought a new position in AbbVie in the 4th quarter valued at about $228,000. Nvest Wealth Strategies Inc. bought a new position in AbbVie in the 4th quarter valued at about $60,000. B. Metzler seel. Sohn & Co. AG lifted its position in AbbVie by 67.2% in the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 833,677 shares of the company's stock valued at $190,659,000 after acquiring an additional 335,055 shares in the last quarter. Milestone Asset Management LLC lifted its position in AbbVie by 276.4% in the 4th quarter. Milestone Asset Management LLC now owns 26,001 shares of the company's stock valued at $5,941,000 after acquiring an additional 19,094 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in AbbVie by 2.6% in the 4th quarter. Teacher Retirement System of Texas now owns 589,752 shares of the company's stock valued at $134,752,000 after acquiring an additional 14,801 shares in the last quarter. Institutional investors own 70.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre advanced manufacturing campus in Durham, NC to produce immunology, neuroscience and oncology medicines; the investment is AbbVie’s largest single-site capital commitment and should support capacity, vertical integration and long‑term growth. AbbVie to build $1.4 billion manufacturing campus in North Carolina
• Positive Sentiment: Canaccord initiated coverage with a strong‑buy/Buy stance and a $262 price target, adding an analyst catalyst and incremental buy-side attention that may support near-term buying interest. AbbVie (ABBV): The Best Stock to Buy on a Pullback
• Positive Sentiment: AbbVie inked an exclusive licensing agreement with Haisco Pharmaceutical Group for pain‑medicine development, extending its pipeline and potential future product/IP upside. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
• Neutral Sentiment: AbbVie is set to report Q1 2026 earnings on April 29; consensus estimates (Zacks) call for revenue around $14.78B and EPS near $2.69 — the print and management commentary could be a short‑term volatility trigger. AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
• Neutral Sentiment: Media and investor pieces highlighting AbbVie as a “buy on a pullback” or attractive dividend/biotech play add background interest but are not immediate catalysts without fresh fundamentals or trial readouts. AbbVie (ABBV): The Best Stock to Buy on a Pullback (InsiderMonkey)
• Negative Sentiment: The U.S. FDA has declined to approve AbbVie’s trenibotulinumtoxinE (TrenibotE) wrinkle treatment, citing manufacturing issues — that regulatory setback delays potential cosmetic-market revenue and introduces execution risk around manufacturing remediation. US FDA declines to approve AbbVie's wrinkle treatment (Reuters)
• Negative Sentiment: AbbVie confirmed receipt of a Complete Response Letter (CRL) from the FDA for the TrenibotE BLA related to manufacturing processes; while the agency did not request new clinical studies, fixing CMC (chemistry, manufacturing, controls) issues can be time‑consuming and costly. AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ABBV shares. Cantor Fitzgerald dropped their price target on shares of AbbVie from $250.00 to $240.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 8th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler dropped their target price on shares of AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a research report on Thursday. The Goldman Sachs Group reissued a "neutral" rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Canaccord Genuity Group started coverage on shares of AbbVie in a research report on Monday. They set a "buy" rating and a $262.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $253.19.

AbbVie Trading Up 0.2%

NYSE:ABBV opened at $200.97 on Friday. The stock has a market capitalization of $355.34 billion, a PE ratio of 85.15, a price-to-earnings-growth ratio of 0.72 and a beta of 0.38. The firm's 50 day moving average is $217.33 and its 200 day moving average is $222.62. AbbVie Inc. has a 12 month low of $176.11 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analysts' expectations of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 EPS. AbbVie's revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts predict that AbbVie Inc. will post 14.22 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's payout ratio is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.